StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)
by Scott Moore · The Cerbat GemStockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a report issued on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Athersys Stock Down 33.5 %
NASDAQ:ATHX opened at $0.01 on Thursday. Athersys has a 52 week low of $0.01 and a 52 week high of $1.99. The stock has a market cap of $833,206.50, a PE ratio of -0.01 and a beta of -0.90.
Athersys Company Profile
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Read More
- Five stocks we like better than Athersys
- How to Read Stock Charts for Beginners
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- 3 Warren Buffett Stocks to Buy Now
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Capture the Benefits of Dividend Increases
- MarketBeat Week in Review – 9/16 – 9/20